Price targets on shares of Bristol Myers Squibb Co. (NYSE: BMY), Agilent Technologies Inc. (NYSE: A), Amarin Co. plc (NASDAQ: AMRN), Apache (NYSE: APA) and Avon Products, Inc. (NYSE: AVP)upgraded by analysts during the last week.
Bank of America (NYSE:BAC) raised their price target on Bristol Myers Squibb Co. (BMY) to $29.00. They have a “neutral” rating on the company.
JPMorgan Chase & Co. (NYSE:JPM) raised their price target on Agilent Technologies Inc. (A) from $53.00 to $59.00. They have an “overweight” rating on the company.
Jefferies (NYSE:JEF) raised their price target on Amarin Co. plc (AMRN) from $21.00 to $25.00. They have a “buy” rating on the company.
Morgan Stanley (NYSE:MS) raised their price target on Apache (APA) from $145.00 to $150.00. They have an “overweight” rating on the company.
Jefferies raised their price target on Avon Products, Inc. (AVP) from $36.00 to $37.00. They have a “buy” rating on the company.
Showing posts with label Amarin Corporation. Show all posts
Showing posts with label Amarin Corporation. Show all posts
Saturday, May 21, 2011
Monday, May 16, 2011
Price Targets on (AMRN) (A) (APA) (AVP) (BMY) Updated
Price targets on Amarin Co. plc (NASDAQ: AMRN), Agilent Technologies Inc. (NYSE: A), Apache (NYSE: APA), Avon Products, Inc. (NYSE: AVP) and Bristol Myers Squibb Co. (NYSE: BMY) were updated by analysts.
Jefferies (NYSE:JEF) raised their price target on Amarin Co. plc (AMRN) from $21.00 to $25.00. They have a “buy” rating on the company.
JPMorgan Chase & Co. (NYSE:JPM) raised their price target on Agilent Technologies Inc. (A) from $53.00 to $59.00. They have an “overweight” rating on the company.
Morgan Stanley (NYSE:MS) raised their price target on Apache (APA) from $145.00 to $150.00. They have an “overweight” rating on the company.
Jefferies raised their price target on Avon Products, Inc. (AVP) from $36.00 to $37.00. They have a “buy” rating on the company.
Bank of America (NYSE:BAC) raised their price target on Bristol Myers Squibb Co. (BMY) to $29.00. They have a “neutral” rating on the company.
Jefferies (NYSE:JEF) raised their price target on Amarin Co. plc (AMRN) from $21.00 to $25.00. They have a “buy” rating on the company.
JPMorgan Chase & Co. (NYSE:JPM) raised their price target on Agilent Technologies Inc. (A) from $53.00 to $59.00. They have an “overweight” rating on the company.
Morgan Stanley (NYSE:MS) raised their price target on Apache (APA) from $145.00 to $150.00. They have an “overweight” rating on the company.
Jefferies raised their price target on Avon Products, Inc. (AVP) from $36.00 to $37.00. They have a “buy” rating on the company.
Bank of America (NYSE:BAC) raised their price target on Bristol Myers Squibb Co. (BMY) to $29.00. They have a “neutral” rating on the company.
Thursday, December 30, 2010
Amarin Corporation (NASDAQ:AMRN) Prime Takeover Candidate After ANCHOR Data
With ANCHOR data in the early part of 2011 expected to be positive for Amarin Corporation (NASDAQ:AMRN), they are soon after expected to be a top candidate to be acquired.
Wedbush analyst Duane Nash says the recent positive data from the Phase III MARINE trial "strongly de-risks the ANCHOR study, as patients in MARINE did not exhibit a rise in LDL cholesterol, an outcome critical for success in ANCHOR."
He added, "relatively low regulatory risk, established market pathway and a growing need for large pharmaceutical companies to augment their cardiovascular drug portfolios to offset the upcoming influx of generic statin (cholesterol lowering) drugs."
Wedbush maintains their "Outperform" rating on Amarin, which closed Wednesday at $8.49, up $0.64, or 8.15 percent. Amarin raised their price target on them from $7 to $10.
Wedbush analyst Duane Nash says the recent positive data from the Phase III MARINE trial "strongly de-risks the ANCHOR study, as patients in MARINE did not exhibit a rise in LDL cholesterol, an outcome critical for success in ANCHOR."
He added, "relatively low regulatory risk, established market pathway and a growing need for large pharmaceutical companies to augment their cardiovascular drug portfolios to offset the upcoming influx of generic statin (cholesterol lowering) drugs."
Wedbush maintains their "Outperform" rating on Amarin, which closed Wednesday at $8.49, up $0.64, or 8.15 percent. Amarin raised their price target on them from $7 to $10.
Wednesday, December 15, 2010
Amarin (Nasdaq:AMRN), Amicus (Nasdaq:FOLD), Dendreon (Nasdaq:DNDN), NPS (Nasdaq:NPSP), Orexigen (Nasdaq:OREX), Pharmasset (Nasdaq:VRUS), Best Biotech Ideas for 2011
Within the small and mid-cap biotech sector, Canaccord Genuity named its best ideas for 2011, which include Amarin (Nasdaq:AMRN), Amicus (Nasdaq:FOLD), Dendreon (Nasdaq:DNDN), NPS Pharmaceuticals (Nasdaq:NPSP), Orexigen (Nasdaq:OREX), Pharmasset (Nasdaq:VRUS) and NPS Pharmaceuticals (Nasdaq:NPSP).
Canaccord said, "We believe that small and mid-cap biotech stock performance will continue to be driven by key catalysts: late-stage clinical data, FDA decisions, and sales growth. In addition to profiling each of our Best Ideas, we are providing quick updates on many of our coverage companies, including what we expect in 2011."
Amarin: AMR101 had positive data from its first pivotal trial in patients with very triglycerides.
Amicus: Amigal for Fabry disease is in a pivotal Phase 3 trial set to yield top-line data in H2/11.
Dendreon is a Best Idea based on blockbuster sales potential for prostate cancer immunotherapy Provenge, fueled in the near term by continued manufacturing and commercial expansion as well as upcoming announcement of a European launch strategy.
NPS Pharmaceuticals is a Best Idea based on 2011 expectations of highly compelling Phase 3 data read-out for previously-validated GATTEX in short bowel syndrome as well as hormone replacement drug NPSP558 in secondary hypoparathyroidism.
Orexigen: Contrave for obesity recently received a positive FDA panel recommendation that we think paves the way for approval in 2011.
Pharmasset: Hepatitis C nuc polymerase inhibitors will be key components of future therapy, in our view. We expect key events in 2011, including: Phase 2b data and a Phase 3 start for Roche-partnered RG7128, Phase2b data for wholly owned PSI-7977, and data from Pharmasset’s proprietary all oral, two-nuc combination study of PSI-938 and PSI-7977.
Amarin closed Tuesday at $5.92, up $0.12, or 2.07 percent. Amicus closed at $4.01, up $0.03, or 0.75 percent. Dendreon ended at $36.28, down $0.28, or 0.77 percent. NPS Pharmaceuticals closed at $7.11, up $0.09, or 1.28 percent. Orexigen closed at $9.01, down $0.01, or 0.11 percent. Pharmasset was up to $47.19, gaining $0.42, or 0.90 percent.
Canaccord said, "We believe that small and mid-cap biotech stock performance will continue to be driven by key catalysts: late-stage clinical data, FDA decisions, and sales growth. In addition to profiling each of our Best Ideas, we are providing quick updates on many of our coverage companies, including what we expect in 2011."
Amarin: AMR101 had positive data from its first pivotal trial in patients with very triglycerides.
Amicus: Amigal for Fabry disease is in a pivotal Phase 3 trial set to yield top-line data in H2/11.
Dendreon is a Best Idea based on blockbuster sales potential for prostate cancer immunotherapy Provenge, fueled in the near term by continued manufacturing and commercial expansion as well as upcoming announcement of a European launch strategy.
NPS Pharmaceuticals is a Best Idea based on 2011 expectations of highly compelling Phase 3 data read-out for previously-validated GATTEX in short bowel syndrome as well as hormone replacement drug NPSP558 in secondary hypoparathyroidism.
Orexigen: Contrave for obesity recently received a positive FDA panel recommendation that we think paves the way for approval in 2011.
Pharmasset: Hepatitis C nuc polymerase inhibitors will be key components of future therapy, in our view. We expect key events in 2011, including: Phase 2b data and a Phase 3 start for Roche-partnered RG7128, Phase2b data for wholly owned PSI-7977, and data from Pharmasset’s proprietary all oral, two-nuc combination study of PSI-938 and PSI-7977.
Amarin closed Tuesday at $5.92, up $0.12, or 2.07 percent. Amicus closed at $4.01, up $0.03, or 0.75 percent. Dendreon ended at $36.28, down $0.28, or 0.77 percent. NPS Pharmaceuticals closed at $7.11, up $0.09, or 1.28 percent. Orexigen closed at $9.01, down $0.01, or 0.11 percent. Pharmasset was up to $47.19, gaining $0.42, or 0.90 percent.
Wednesday, December 1, 2010
Canaccord Reiterates "Buy" on Amarin (NASDAQ:AMRN)
Canaccord Genuity has maintained their "Buy" rating on Amarin Corporation (NASDAQ:AMRN), citing strong chances of FDA approval for AMR101.
"We think MARINE data bodes well for Q2/11 ANCHOR data; raising target on increased chances of FDA approval. AMR101 is AMRN’s purified EPA omega-3 drug for high triglycerides. We expect release of very positive complete MARINE data and top-line ANCHOR pivotal trial data in H1/11. We think AMRN may submit the AMR101 NDA for very high triglycerides in mid-2011 and get approval in H1/12," said Canaccord.
Amarin closed Tuesday at $5.83, dropping slightly by $0.02, or 0.34 percent. Canaccord raised their price target on them from $7 to $9.
Trading volume soared from the 3-month average of 1,657,530 to 14,537,395.
"We think MARINE data bodes well for Q2/11 ANCHOR data; raising target on increased chances of FDA approval. AMR101 is AMRN’s purified EPA omega-3 drug for high triglycerides. We expect release of very positive complete MARINE data and top-line ANCHOR pivotal trial data in H1/11. We think AMRN may submit the AMR101 NDA for very high triglycerides in mid-2011 and get approval in H1/12," said Canaccord.
Amarin closed Tuesday at $5.83, dropping slightly by $0.02, or 0.34 percent. Canaccord raised their price target on them from $7 to $9.
Trading volume soared from the 3-month average of 1,657,530 to 14,537,395.
Subscribe to:
Posts (Atom)